ONDINE BIOMEDICAL INC.CDI
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more
Market Cap & Net Worth: ONDINE BIOMEDICAL INC.CDI (VF5)
ONDINE BIOMEDICAL INC.CDI (F:VF5) has a market capitalization of $69.17 Million (€67.39 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #23280 globally and #2537 in its home market, demonstrating a 4.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONDINE BIOMEDICAL INC.CDI's stock price €0.13 by its total outstanding shares 518366964 (518.37 Million).
ONDINE BIOMEDICAL INC.CDI Market Cap History: 2022 to 2026
ONDINE BIOMEDICAL INC.CDI's market capitalization history from 2022 to 2026. Data shows change from $110.67 Million to $69.17 Million (-31.79% CAGR).
ONDINE BIOMEDICAL INC.CDI Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONDINE BIOMEDICAL INC.CDI's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VF5 by Market Capitalization
Companies near ONDINE BIOMEDICAL INC.CDI in the global market cap rankings as of March 19, 2026.
Key companies related to ONDINE BIOMEDICAL INC.CDI by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ONDINE BIOMEDICAL INC.CDI Historical Marketcap From 2022 to 2026
Between 2022 and today, ONDINE BIOMEDICAL INC.CDI's market cap moved from $110.67 Million to $ 69.17 Million, with a yearly change of -31.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €69.17 Million | +69.93% |
| 2025 | €40.70 Million | -1.29% |
| 2024 | €41.24 Million | +1.97% |
| 2023 | €40.44 Million | -63.46% |
| 2022 | €110.67 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ONDINE BIOMEDICAL INC.CDI was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $69.17 Million USD |
| MoneyControl | $69.17 Million USD |
| MarketWatch | $69.17 Million USD |
| marketcap.company | $69.17 Million USD |
| Reuters | $69.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.